The Palmoplantar Psoriasis Global Assessment (PPPGA) is a physician-administered tool used to assess the severity of palmoplantar psoriasis, primarily affecting the hands and feet. This evaluation is essential in determining treatment approaches and monitoring the disease’s impact on a patient’s quality of life.
The PPPGA rates psoriasis severity on a scale from 0 to 4 based on erythema (redness), scaling, and the presence of pustules and fissures:
Reference
Apremilast, An Oral Phosphodiesterase-4 Inhibitor, in the Treatment of Palmoplantar Psoriasis: Results of a Pooled Analysis from Phase II PSOR-005 and Phase III ESTEEM Clinical Trials in Patients with Moderate to Severe Psoriasis. Bissonnette R, Pariser DM, Wasel NR, et al. J Am Acad Dermatol. 2016;75:99-105.
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
